monoclonal antibody
FDA Approves Enflonsia, Second RSV Antibody for Infants
The FDA has approved the second monoclonal antibody for the prevention of RSV in neonates and infants, ...
JUNE 10, 2025
mAb Effective at Preventing Malaria
One dose of a monoclonal antibody (mAb) safely protected healthy, nonpregnant adults from malaria infection during ...
DECEMBER 10, 2022
FDA Withdraws Sotrovimab for COVID-19 Treatment
The FDA has withdrawn the emergency use authorization for sotrovimab (Xevudy, GSK/Vir) to treat COVID-19 due to ...
APRIL 7, 2022
FDA: Sotrovimab Ineffective Against New Omicron Subvariant
The FDA limited the EUA for sotrovimab in parts of the United States, because the authorized dose is unlikely to be ...
MARCH 31, 2022
Disparities Exist Among Recipients of COVID-19 Therapies
People who identify as Hispanic, Black, Asian or other racial minority groups are far less likely to receive ...
FEBRUARY 10, 2022
FDA Limits Use of Monoclonal Antibodies to Treat COVID-19
The FDA revised the EUAs for two monoclonal antibody cocktails for COVID-19, essentially saying the should not be ...
JANUARY 25, 2022
Regen-COV Reduces Viral Load in Patients Hospitalized with COVID-19
The monoclonal antibody cocktail may be as useful in the hospital as it is in the outpatient setting.
OCTOBER 2, 2021
JAK Inhibitors, IL-6 Blockers for COVID-19: Where Do They Fit?
Another JAK inhibitor appears effective in reducing death and respiratory failure in patients hospitalized with ...
JULY 6, 2021
FDA Authorizes Lower Dose of Regen-Cov mAb Cocktail
The FDA updated the emergency use authorization (EUA) for Regeneron’s Regen-Cov, lowering the dose to 1,200 ...
JUNE 4, 2021
Monoclonal Antibody Therapy Underused
More people with COVID-19 should be taking monoclonal antibodies, experts said.
FEBRUARY 10, 2021
FDA Authorizes Lilly MAB Cocktail for COVID-19
A second monoclonal antibody cocktail receives an emergency use authorization to treat less severe cases of ...
FEBRUARY 10, 2021
FDA Authorizes MAB Cocktail for Treatment of COVID-19
Casirivimab and imdevimab should be administered together for the treatment of mild to moderate COVID-19 patients ...
NOVEMBER 24, 2020
